XLXing-Le Liang

Xing-Le Liang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xing-Le Liang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Fang Tang

    Department of Chronic Disease Management, The Second Clinical College, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, China

    1 shared publication
  • Hui-Fen Chen

    Chinese Medicine Guangdong Laboratory, Department of Nephrology, The Second Clinical College, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, China

    1 shared publication
  • Li-Zhe Fu

    Department of Chronic Disease Management, The Second Clinical College, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, China

    1 shared publication
  • Tao Zou

    Department of Chronic Disease Management, The Second Clinical College, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, China

    1 shared publication
  • Wenwei Ouyang

    Key Unit of Methodology in Clinical Research, The Second Clinical College, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China

    1 shared publication
  • Xian-Long Zhang

    Chinese Medicine Guangdong Laboratory, Department of Nephrology, The Second Clinical College, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, China

    1 shared publication

Latest Publications

  • Open Access

    Self‐Management Improves Long‐Term CKD Prognosis: A 10‐Year Retrospective Cohort Study From China

    by Hui-Fen Chen, Xing-Le Liang, Yan Han, Yu-Han Shen, Xian-Long Zhang, Fang Tang, Li-Zhe Fu, Yue-Yu Gu, Tao Zou, Xin-Dong Qin, et al.

    Background: Self‐management (SMP) is a novel treatment comprised of multidimensional interventions. Researchers have reported its reliable effects on short‐term improvements in surrogate indicators like 24‐h urinary protein excretion and systolic blood pressure. However, whether it has any effect on long‐term changes in other surrogate indicators and chronic kidney disease (CKD) endpoints remains unclear. Methods: Patients with CKD stages 3‐4 were grouped into either a SMP group or a nonself‐management (non‐SMP) group whether they had complied any of five characterized elements: regular visits, medication adjustment, nutritional intervention, lifestyle modification, education, and behavior guide. We used 1:1 nearest‐neighbor propensity score matching (PSM) to balance between‐group differences. Cox regression was used to explore the long‐term association between SMP and composite outcomes (all‐cause mortality, end‐stage kidney disease (ESKD), ≥ 50% decline in estimated glomerular filtration rate (eGFR), or doubling of serum creatinine (SCr) from baseline). Linear mixed‐effects (LME) model and marginal means comparisons were used to surrogate indicators analysis. Results: The study included 1160 patients with a median follow‐up of 27.20 months. Among them, 580 individuals were in the SMP group and 580 were in the non‐SMP group. In the non‐SMP group, the median follow‐up was 24.48 (12.21, 43.39) months with 174 (30.00%) events, whereas the SMP group had a median follow‐up of 29.34 (14.75, 42.00) months with 134 (23.10%) composite outcomes. Participation in a SMP program was associated with a 30.9% reduction in CKD progression risk (hazard ratio (HR) of composite outcome: 0.691, 95% CI: 0.549–0.869, and p = 0.002). LME and marginal means comparison indicated that patients with SMP had higher mean difference of eGFR and serum albumin (Alb) than the non‐SMP individuals (mean difference of eGFR: 1.791 (0.721, 2.861) mL/min/1.73 m 2 , p = 0.001; marginal mean difference of eGFR: 2.560 (1.660, 3.470) mL/min/1.73 m 2 , p < 0.0001; mean difference of Alb: 0.654 (0.202, 1.105) g/L, p = 0.005; and marginal mean difference of Alb: 0.460 (0.166, 0.753) g/L, p = 0.002). Conclusion: SMP programs are associated with a 30.9% reduction in CKD progression risk and improvements in kidney function and nutrition‐related surrogate markers, benefiting CKD patients in stages 3‐4.